Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
major depressive disorder
Biotech
Xenon pauses ph. 3 depression trials after psychosis events
The company has voluntarily stopped enrolling new patients in the studies in response to reports of mostly mild or moderate adverse events.
Nick Paul Taylor
Sep 18, 2026 6:03am
J&J-Contineum depression drug flunks another ph. 2 test
Sep 15, 2026 4:40am
Definium’s LSD depression drug produces ‘best ever’ ph. 3 data
Jun 22, 2026 7:00am
GLP-1s may combat depression through a mood-boosting gut microbe
Jun 10, 2026 11:00am
Compass, Usona and Transcend score priority vouchers amid psychedelic push
Apr 24, 2026 3:51pm
Biohaven flunks depression trial, adding to CNS release concerns
Jan 2, 2026 4:48am
